

Table 4: Subgroup Analyses for oral oseltamivir versus inhaled zanamivir

Outcome	Confirmed influenza	Age	Baseline risk (e.g. immune-compromised)	Dosage of antiviral	Type of Influenza A vs B	Pandemic versus Seasonal	Severity of Influenza	Funding Conflict
Mortality	-	-	-	-	-	-	-	-
Time to alleviation of symptoms	-	NS	-	-	Influenza A 0.23 (0.12, 0.34) Influenza B 0.52 (0.33, 0.70) P=0.009	-	-	-
Adverse events	-	-	-	-	-	-	-	-
Viral shedding	-	-	-	-	-	-	-	-

“-” indicates insufficient data to test for subgroup interactions; NS indicates non significant interaction